News&Press

Publications

Smad7 Controls Immunoregulatory PDL2/1-PD1 Signaling in Intestinal Inflammation and Autoimmunity

2019.09.24

Publications

Smad7 Antisense Oligonucleotide in Crohn’s Disease: A Re-Evaluation and Explanation for the Discordant Results of Clinical Trials

2022.12.28

Publications

Smad7 as a positive regulator of intestinal inflammatory diseases

2023.01.24

News, Press

Nogra Pharma announces out-licensing agreement with Torii Pharmaceutical for Japan for New Chemical Entity topical acne treatment

2023.01.26

Publications

GED-0507 is a novel potential antifibrotic treatment option for pulmonary fibrosis

2020.03.12

Publications

Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs

2017.12.12

Publications

PPAR Gamma: From Definition to Molecular Targets and Therapy of Lung Diseases

2021.01.15

Publications

The role of PPARγ-mediated signalling in skin biology and pathology: new targets and opportunities for clinical dermatology

2015.02.03

Publications

Commentary on ‘Sebocyte differentiation as a newtarget for acne therapy: an in vivo experience

2020.07.31

Publications

Sebocyte differentiation as a new target for acne therapy: an in vivo experience

2020.01.30

Publications

Pharmacological PPARγ modulation regulates sebogenesis and inflammation in SZ95 human sebocytes

2017.08.15

Publications

Preclinical Studies of a Specific PPARγ Modulator in the Control of Skin Inflammation

2013.11.21

Publications

Efficacy and safety of N-acetyl-GED-0507-34-LEVO gel in patients with moderate-to severe facial acne vulgaris: a phase IIb randomized double-blind, vehicle-controlled trial

2022.05.12

Publications

Targeting Peroxisome Proliferator-Activated Receptors (PPARs): Development of Modulators

2012.01.19

Publications

Role of AHR Ligands in Skin Homeostasis and Cutaneous Inflammation

2021.11.15

Publications

AHR in the intestinal microenvironment: safeguarding barrier function

2021.03.19

Publications

Anti-Inflammatory and Pro-Differentiating Properties of the Aryl Hydrocarbon Receptor Ligands NPD-0614-13 and NPD-0614-24: Potential Therapeutic Benefits in Psoriasis

2021.07.13

Publications

NPD-0414-2 and NPD-0414-24, Two Chemical Entities Designed as Aryl Hydrocarbon Receptor (AhR) Ligands, Inhibit Gut Inflammatory Signals

2019.04.12

Publications

Aryl Hydrocarbon Receptor-Induced Signals Up-regulate IL-22 Production and Inhibit Inflammation in the Gastrointestinal Tract

2011.01.11

Publications

A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open‑Label Study

2021.04.19

Publications

Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease

2015.03.19

Publications

Inhibition of Smad7 With a Specific Antisense Oligonucleotide Facilitates TGF-β1–Mediated Suppression of Colitis

2006.12.01

Publications

Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn’s Disease

2018.01.01

Publications

Inhomogeneous Diastereomeric Composition of Mongersen Antisense Phosphorothioate Oligonucleotide Preparations and Related Pharmacological Activity Impairment

20220804

Publications

Smad7 Sustains Stat3 Expression and Signaling in Colon Cancer Cells

2022.10.12

Publications

Mongersen (GED-0301) for Active Crohn’s Disease: Results of a Phase 3 Study

2020.05.08

Publications

Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs

2017.12.12

Publications

Phase I Clinical Trial of Smad7 Knockdown Using Antisense Oligonucleotide in Patients With Active Crohn’s Disease

2012.01.17

Nogra Pharma is available to give comprehensive Project presentations, provide additional Project specific details/confidential information and discuss potential collaborations or out-licensing opportunities with interested companies.